UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1373-5
Program Prior Authorization/Notification
Medication Livmarli™ (maralixibat)
P&T Approval Date 11/2021, 11/2022, 5/2023, 5/2024, 9/2024
Effective Date 12/1/2024
1. Background:
Livmarli (maralixibat) is an ileal bile acid transporter inhibitor indicated for the treatment of
cholestatic pruritis in patients 12 months of age and older with progressive familial intrahepatic
cholestasis (PFIC). Livmarli is also indicated for the treatment of cholestatic pruritis in patients
3 months of age and older with Alagille syndrome (ALGS).
Limitation of Use:
Livmarli is not recommended in a subgroup of PFIC type 2 patients with specific ABCB11
variants resulting in non-functional or complete absence of bile salt export pump (BSEP) protein.
2. Coverage Criteriaa:
A. Progressive Familial Intrahepatic Cholestasis
1. Initial Authorization
a. Livmarli will be approved based upon both of the following criteria:
(1) Diagnosis of progressive familial intrahepatic cholestasis (PFIC)
-AND-
(2) Patient is experiencing pruritus associated with PFIC.
Authorization will be issued for 12 months.
2. Reauthorization
a. Livmarli will be approved based on the following criterion:
(1) Documentation of positive clinical response to Livmarli therapy
Authorization will be issued for 12 months.
B. Alagille Syndrome
1. Initial Authorization
a. Livmarli will be approved based upon both of the following criteria:
© 2024 UnitedHealthcare Services, Inc.
1
(1) Diagnosis of Alagille syndrome (ALGS).
-AND-
(2) Patient is experiencing pruritus associated with ALGS.
Authorization will be issued for 12 months.
2. Reauthorization
a. Livmarli will be approved based on the following criterion:
(1) Documentation of positive clinical response to Livmarli therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
• Supply limits may be in place.
4. Reference:
1. Livmarli [package insert]. Foster City, CA: Mirum Pharmaceuticals, Inc.; July 2024.
Program Prior Authorization/Notification - Livmarli (maralixibat)
Change Control
11/2021 New program
11/2022 Annual review with no changes to coverage criteria. Added state
mandate footnote.
5/2023 Updated background with expanded indication in ALGS patients 3
months of age and older. No change to coverage criteria. Updated
reference.
5/2024 Annual review. Added coverage criteria for new PFIC indication.
Updated initial authorization duration to 12 months for ALGS
indication. Updated background and reference.
9/2024 Updated background with expanded PFIC indication in patients 12
months to 4 years of age. Updated reference.
© 2024 UnitedHealthcare Services, Inc.
2